Adipotide and AOD-9604 Interaction: Monitor | Peptide Database

Many peptides discussed on this website are research chemicals that are not approved by the FDA for human use. Information about dosing, effects, and protocols is derived from published research studies, clinical trials, and user reports. This information is provided for educational purposes only.

Irreversibly inactivates aromatase to reduce estradiol levels during testosterone or aromatizable anabolic steroid cycles. The absence of estrogen rebound makes exemestane particularly useful when discontinuing AI support, such as transitioning into PCT. Manages estrogen-mediated fluid retention and subcutaneous bloating common with testosterone and other aromatizable compounds. The mild androgenic activity of exemestane may complement the drier appearance. Titrated to keep estradiol within a healthy range during hormone replacement or enhancement protocols. Because inhibition is irreversible, overshooting the dose requires waiting for new aromatase synthesis rather than simply skipping doses. Bloodwork is essential. FDA-approved for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy, and as adjuvant therapy after 2-3 years of tamoxifen. The IES trial demonstrated improved disease-free survival when switching to exemestane after initial tamoxifen treatment. Used off-label alongside TRT to manage estradiol elevations. The irreversible mechanism and mild androgenic properties make it an alternative to anastrozole for men who experience excessive joint pain or mood disturbance on nonsteroidal AIs. Exemestane's irreversible mechanism prevents the estrogen rebound that can occur when stopping a reversible AI like anastrozole at the end of a cycle. This makes it well-suited for managing estrogen during the transition into post-cycle therapy with SERMs.